Overview

* OrthoPediatrics ( KIDS ) Q3 prelim revenue grows 12% yr/yr to $61.2 mln, missing analyst expectations

* Company revises 2025 revenue guidance due to delayed 7D capital sales

* OrthoPediatrics ( KIDS ) faces headwinds in Latin and South America, impacting revenue

Outlook

* OrthoPediatrics ( KIDS ) lowers 2025 revenue guidance to $233.5 mln-$234.5 mln

* Company maintains 2025 adjusted EBITDA guidance at $15 mln-$17 mln

* OrthoPediatrics ( KIDS ) sees minimal sales growth from Latin and South America

Result Drivers

* DELAYED SALES - Delayed 7D capital sales and timing of set sales in Latin and South America impacted revenue growth

* INTERNATIONAL CHALLENGES - Prelim international revenue grew 6% yr/yr, affected by timing of set sales and large stocking orders

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $61.20 $63.60

Revenue mln mln (7

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for OrthoPediatrics Corp ( KIDS ) is $35.00, about 48.3% above its October 8 closing price of $18.10

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)